Clinical Observation of Ambroxol Combined with Naloxone in the Treatment of AECOPD with Respiratory Failure

Abstract

Objective: This study aims to analyze the effects of ambroxol combined with naloxone in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients with respiratory failure. Methods: 100 patients with AECOPD complicated with respiratory failure admitted to our hospital from January 2020 to February 2021 were divided into a control group and an observation group by random number table method. Patients in both groups received conventional treatment combined with low-flow oxygen therapy. Control group patients were given naloxone on this basis, while observation group patients were additionally given ambroxol combined with naloxone. Lung function, blood gas index levels, immune function, inflammatory factor levels and adverse reactions were compared between the two groups. Results: After treatment, levels of forced vital capacity (FVC), forced expiratory volume in the first second (FEV₁), peak expiratory flow rate (PEF), arterial partial pressure of oxygen (PaO₂), CD4⁺ and CD4⁺/CD8⁺ of patients in two groups were increased while partial pressure (PaCO₂) and CD8⁺ levels were declined. Additionally, changes in these indexes were more apparent in the observation group than in the control group. C-reactive protein (CRP), tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) levels of patients in both groups were sharply abated after treatment, and these levels in the observation group were lower than those in the control group. Adverse reactions of patients in both groups showed no significant difference. Conclusion: Ambroxol combined with naloxone and low-flow oxygen therapy safely improves lung function and immune function, regulates blood gas index levels and reduces the inflammatory response in AECOPD patients with respiratory failure.